12/19
08:44 am
crdl
PRISM MarketView Features Q&A with President and CEO David Elsley: Cardiol Therapeutics Enters Phase 3 Clinical Trial for CardiolRx™ Addressing Patients with Recurrent Pericarditis [Yahoo! Finance]
Low
Report
PRISM MarketView Features Q&A with President and CEO David Elsley: Cardiol Therapeutics Enters Phase 3 Clinical Trial for CardiolRx™ Addressing Patients with Recurrent Pericarditis [Yahoo! Finance]
12/19
08:30 am
crdl
PRISM MarketView Features Q&A with President and CEO David Elsley: Cardiol Therapeutics Enters Phase 3 Clinical Trial for CardiolRx™ Addressing Patients with Recurrent Pericarditis
Low
Report
PRISM MarketView Features Q&A with President and CEO David Elsley: Cardiol Therapeutics Enters Phase 3 Clinical Trial for CardiolRx™ Addressing Patients with Recurrent Pericarditis
12/18
08:07 am
crdl
Cardiol Therapeutics Inc. (NASDAQ: CRDL) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $9.00 price target on the stock.
Low
Report
Cardiol Therapeutics Inc. (NASDAQ: CRDL) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $9.00 price target on the stock.
11/20
11:17 am
crdl
Trends in the $6 Billion Botanical Drugs Industry, 2030: An Assessment of Emerging Growth Opportunities and Strategic Developments [Yahoo! Finance]
Low
Report
Trends in the $6 Billion Botanical Drugs Industry, 2030: An Assessment of Emerging Growth Opportunities and Strategic Developments [Yahoo! Finance]
11/20
08:06 am
crdl
Cardiol Therapeutics Inc. (NASDAQ: CRDL) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $9.00 price target on the stock.
Medium
Report
Cardiol Therapeutics Inc. (NASDAQ: CRDL) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $9.00 price target on the stock.
11/13
08:00 am
crdl
Cardiol Therapeutics Inc. Added to PRISM Emerging Biotech Index
Medium
Report
Cardiol Therapeutics Inc. Added to PRISM Emerging Biotech Index
10/24
08:08 am
crdl
Cardiol Therapeutics Inc. (NASDAQ: CRDL) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $9.00 price target on the stock.
Low
Report
Cardiol Therapeutics Inc. (NASDAQ: CRDL) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $9.00 price target on the stock.
10/22
10:56 am
crdl
Are Medical Stocks Lagging Cardiol Therapeutics (CRDL) This Year? [Yahoo! Finance]
Low
Report
Are Medical Stocks Lagging Cardiol Therapeutics (CRDL) This Year? [Yahoo! Finance]
10/11
08:44 am
crdl
US producer prices unchanged in September [Yahoo! Finance Canada]
Medium
Report
US producer prices unchanged in September [Yahoo! Finance Canada]
10/9
08:15 am
crdl
Cardiol Therapeutics Announces Pricing of Public Offering of Common Shares [Yahoo! Finance]
High
Report
Cardiol Therapeutics Announces Pricing of Public Offering of Common Shares [Yahoo! Finance]
10/7
03:15 am
crdl
Terry Lynch Joins BioNxt as Capital Markets Advisor [Yahoo! Finance]
Medium
Report
Terry Lynch Joins BioNxt as Capital Markets Advisor [Yahoo! Finance]
9/24
07:30 am
crdl
Cardiol Therapeutics Achieves Target Patient Enrollment in its Phase II ARCHER Trial Investigating CardiolRx(TM) for Acute Myocarditis [Yahoo! Finance]
Medium
Report
Cardiol Therapeutics Achieves Target Patient Enrollment in its Phase II ARCHER Trial Investigating CardiolRx(TM) for Acute Myocarditis [Yahoo! Finance]